Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Rapid Therapeutic Science Laboratories, Inc. (RTSL)
|
Add to portfolio |
|
|
|
| Price: |
$0.24
| | Metrics |
| OS: |
8.83
|
M
| |
|
|
| Market cap: |
$2.13
|
M
| |
|
|
|
Net debt:
|
$10.2
|
M
| |
|
|
|
EV:
|
$12.3
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 |
| Revenues | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -99.6% | | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 4.3 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.1 | 0.0 | 0.0 | -4.3 | 0.0 | 0.0 | 0.0 |
| Gross margin | 62.5% | 85.2% | 21.7% | | | | | |
| Selling, general and administrative | | | | | | | 0.0 | |
| General and administrative | 2.1 | 2.0 | 0.4 | 0.2 | 0.1 | 0.0 | | 0.0 |
| EBITA | -0.8 | -1.9 | -0.2 | 0.0 | -2.5 | 0.0 | 0.0 | 0.0 |
| EBITA margin | -151141.4% | -1421.6% | -2231.3% | | | | | |
| Amortization of intangibles | 0.0 | 0.1 | 0.0 | | | | | |
| EBIT | -0.8 | -1.9 | -0.2 | 0.0 | -2.5 | 0.0 | 0.0 | 0.0 |
| EBIT margin | -157463.3% | -1478.9% | -2641.7% | | | | | |
| Pre-tax income | -2.9 | -2.1 | -0.6 | -0.3 | -2.6 | 0.0 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Net income | -2.9 | -2.1 | -0.6 | -0.3 | -2.6 | 0.0 | 0.0 | 0.0 |
| Net margin | -537056.7% | -1567.5% | -6834.3% | | | | | |
| |
| Diluted EPS | ($0.02) | ($0.01) | ($0.01) | ($0.29) | ($1.04) | ($0.01) | | |
| Shares outstanding (diluted) | 190.7 | 168.8 | 60.0 | 1.2 | 2.5 | 2.7 | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|